The currently known main phenotype of loss of NHA2 being an insulin secretion deficit and reduced blood pressure mediated by reduced activation of the WNK-SPAK-NCC axis, drug development could focus on these two metabolic diseases, diabetes mellitus and arterial hypertension. Here, SLC9B2 is linked to Hypertension.